Institutional members access full text with Ovid®

New Antidiabetic Drug in Three Preparations

Aschenbrenner, Diane S. MS, RN

AJN, American Journal of Nursing: May 2013 - Volume 113 - Issue 5 - p 26
doi: 10.1097/01.NAJ.0000430229.99197.75
Drug Watch

* Alogliptin (Nesina) is the newest dipeptidyl peptidase-4 inhibitor approved for the treatment of type 2 diabetes. It's also available as part of two combination therapies—called Kazano when combined with metformin and Oseni when combined with pioglitazone.

* The most common adverse effects are upper respiratory infections, nasopharyngitis, and headache. Alogliptin may also cause acute pancreatitis, severe liver disease, and severe allergic reactions. Hypoglycemia is possible if the drug is administered with a sulfonylurea or with insulin.

Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: daschen1@jhu.edu.

© 2013 Lippincott Williams & Wilkins, Inc.